Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions
- 21 April 2026
- journal article
- review article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (4) , 103117
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in AdultsJAMA, 2026
- Combining Medications With Bariatric Surgery to Treat ObesityJAMA, 2026
- New Molecules and Indications for GLP-1 MedicinesJAMA, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or ObesityJAMA Internal Medicine, 2024
- Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and SuicidalityJAMA Network Open, 2024
- Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before AnesthesiaJAMA Surgery, 2024
- Obesity Management in AdultsJAMA, 2023
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021